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Background: Olanzapine rapid-acting intramuscular (IM) injection is an atypical antipsychotic drug already used
overseas and recently approved in Japan. The objective of this study was to confirm the efficacy of rapid-acting IM
olanzapine 10 mg was greater than IM placebo in patients with exacerbation of schizophrenia with acute psychotic
agitation by comparing changes from baseline to 2 hours after the first IM injection, as measured by the Positive
and Negative Syndrome Scale-Excited Component (PANSS-EC) total score.
Methods: We conducted a placebo-controlled, randomized, double-blind, parallel-group study in Japanese patients
diagnosed with schizophrenia according to the diagnostic criteria specified in the DSM-IV-TR. Patients were
randomized to 2 treatment groups: IM olanzapine (10 mg) or IM placebo. The primary efficacy outcome was the
change in PANSS-EC from baseline to 2 hours after the first IM injection. Treatment groups were compared with an
analysis of variance model which included treatment and site as factors. During the 24-hour treatment period,
safety was assessed by clinical examination and laboratory investigations, electrocardiograms, extrapyramidal
symptoms scales, and recording spontaneously reported adverse events.
Results: Of the 91 randomized patients, 90 patients (45 IM olanzapine-group; 45 IM placebo-group) were in the full
analysis set. The mean change of PANSS-EC total score from baseline to 2 hours after the first IM injection (mean
±standard deviation) was −9.2±4.5 for the IM olanzapine group and −2.8±5.6 for the IM placebo group. The
difference between treatment groups was statistically significant (p<.001). There were no deaths, serious adverse
events, treatment-emergent adverse events (TEAEs) leading to discontinuation, severe TEAEs, or instances of
oversedation in this study. There were no statistically significant differences between treatment groups in the
proportion of patients with potentially clinically significant changes in laboratory tests, vital signs (blood pressure
and pulse rate), electrocardiograms, and treatment-emergent extrapyramidal symptoms.
Conclusion: The efficacy of IM olanzapine 10 mg in patients with exacerbation of schizophrenia with acute
psychotic agitation was greater than IM placebo in the primary efficacy measure, PANSS-EC. Intramuscular
olanzapine 10 mg was shown to be generally safe and tolerable, and could be a new option for treatment of
schizophrenia in Japan.
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Schizophrenia is a chronic disease, but in the acute phase
agitation is common and may be accompanied by destruc-
tive and/or violent behavior [1-5]. In those cases, patients
should be calmed as soon as possible to achieve a state of
calm sufficient to minimize the risk posed to them or to
others. Typical injections, such as a haloperidol injection,
have been frequently used to calm patients with severe
agitation [6]. However, intramuscular (IM) typical neuro-
leptics have been associated with undesirable side effects,
including acute dystonia [7], malignant syndrome [8] and
abnormal electrocardiograms including corrected QT
interval (QTc) prolongation [9-11]. Currier and Simpson’s
2001 study suggested that treatment with risperidone li-
quid concentrate and oral lorazepam was a tolerable and
comparable alternative to IM haloperidol and lorazepam
for short-term treatment of agitated psychosis in patients
who accept oral medications [12]. In addition, olanzapine
orally disintegrating tablet versus risperidone oral solution
yielded similar improvements in acutely agitated patients
who accepted oral medication [13]. Oral medications are
considered to be preferable to parenteral administra-
tion [14]. Therefore, oral solutions have become used
more frequently than injections to calm patients who
have agitation, but patients with severe agitation do
not always take oral medications. Antipsychotic injections
allow physicians to treat the patients, but also could be
expected to calm patients more rapidly than oral medica-
tions [15]. Therefore, antipsychotic injections are still an
option, especially to calm agitated patients who refuse to
take medications.
A rapid-acting IM olanzapine was developed for rapid
tranquilization of patients with acute-phase schizophre-
nia (exacerbation of schizophrenia with acute psychotic
agitation) requiring parenteral drug therapy. Currently,
IM olanzapine has been approved in more than 83 coun-
tries including in the United States and various countries
in the European Union, and was approved in Japan in
2012. The original worldwide development of IM
olanzapine did not include patients in Japan, so a Japan-
specific development plan was undertaken. In Japan, oral
olanzapine was approved in 2000 for the indication of
schizophrenia, 2010 for improvement of manic symptoms
in bipolar disorder, and in 2012 for improvement of de-
pressive symptoms in bipolar disorder. Although intro-
duction of oral atypical antipsychotics to Japan broadened
treatment options for patients with schizophrenia, and
rapid-acting injectable atypical antipsychotics only recently
became available. Intramuscular olanzapine has a generally
favorable profile with regard to extrapyramidal symptoms,
QTc prolongation and oversedation [16-19]. In addition,
IM olanzapine is positioned as one of the first-line agents
for treatment of acute phase schizophrenia requiring IM
pharmacotherapy out of Japan [4,20].A randomized, placebo-controlled, double-blind study of
IM olanzapine in Japanese patients with an exacerbation of
schizophrenia with acute psychotic agitation was con-
ducted. The primary objective of the study was to confirm
the efficacy of IM olanzapine (10 mg) was greater
than efficacy of IM placebo in Japanese patients who
had exacerbation of schizophrenia with acute psychotic
agitation. Efficacy was measured by comparing the change
from baseline to 2 hours after the first IM injection in the
Positive and Negative Syndrome Scale-Excited Component
(PANSS-EC) total score [21,22]. We report the results of
this study in this paper.
Methods
Study design and patient selection
This was a multicenter, placebo-controlled, randomized,
double-blind, parallel-group study in Japanese patients
diagnosed with schizophrenia according to the diagnos-
tic criteria specified in the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text
Revision (DSM-IV-TR). Outpatients with an exacerbation
of schizophrenia with acute psychotic agitation who
required hospitalization at a regular doctor visit or in
an emergency room, and inpatients with acute psychotic
agitation were eligible for this study. Patients with acute
psychotic agitation were defined as those who met any of
following 3 criteria: patients whose agitation occurred or
worsened within the prior 2 weeks, patients who were
considered to require rapid tranquilization, or patients
who needed careful consideration for examination or
treatment (for example, more than 1 medical staff,
special room).
The exclusion criteria in the current study were (1)
patients whose agitation continued more than 2
weeks before providing informed consent, (2) patients
whose agitation was caused by substance abuse,
neurologic conditions or the comorbidity of mental
retardation or personality disorders, and (3) patients
who had inadequately controlled diabetes, or patients
whose treatments for diabetes had been changed
within 4 weeks before the first IM injection of the
investigational product.
The study population was composed of patients who
had met DSM-IV-TR criteria for schizophrenia, who were
at least 20 years of age and less than 65 years of age who
had exacerbation of schizophrenia with acute psychotic
agitation, and with an Agitation-Calmness Evaluation
Scale (ACES Eli Lilly and Company, Indianapolis, Indiana;
©1998, All rights reserved) score of 1 or 2 before the
first IM injection of the investigational product. The
ACES is a single-item scale developed by Eli Lilly
and Company on which 1 indicates Marked Agita-
tion; 2, Moderate Agitation; 3, Mild Agitation; 4,
Normal; 5, Mild Calmness; 6, Moderate Calmness; 7,
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[16,23].
Intervention
Use of drugs considered to affect the central nervous
system was prohibited as a rule from 2 hours prior to
the initial administration of the study drug to 24 hours
after the administration. Conditional use of oral drugs was
allowed. Oral administration of benzodiazepine hypnotics
and anti-anxiety drugs was allowed only when the conti-
nued treatment with them was difficult to stop and a new
treatment was required for adverse events excluding the
period from 4 hours before to 2 hours after the adminis-
tration. Anticholinergic agents were allowed from 2 hours
before administration of the study drug to the end of the
study only when the treatment was continuously used and
could not be stopped or it was used as a new treatment
for adverse events.
Patients were randomized to 2 treatment groups: IM
olanzapine (10 mg) or IM placebo. All patients received at
least 1 injection in the upper outer quadrant of the gluteus
maximus muscles. If the investigator or subinvestigator(s)
determined that the patient had no response or unsatisfac-
tory efficacy after the first IM injection of the investiga-
tional product, the patient was permitted to receive a
second IM injection. The second IM injection was admi-
nistered at the same dose as the first IM injection, during
the period from the completion of assessments scheduled
for 2 hours after the first IM injection to 4 hours after the
first IM injection.
Efficacy and safety analysis
The primary efficacy measure was the change from base-
line to 2 hours after the first IM injection as measured
by PANSS-EC total score. The changes at 15, 30, 60, and
90 minutes and 24 hours after the administration were
also compared between the treatment groups. PANSS-EC
consists of the following 5 items: Excitement, Hostility,
Tension, Uncooperativeness, and Poor Impulse Control.
[21,22] Each item was rated on a scale from 1 (Absent) to
7 (Extreme). The sum of these ratings for all 5 items is
defined as the PANSS-EC total score which ranged from 5
to 35. The secondary efficacy measures were ACES and
the response to the investigational product. The propor-
tion of patients who showed an ACES score of 4 (Normal)
to 7 (Severe Sedation) at 30, 60, and 90 minutes and
2 and 24 hours after the initial administration was
compared between treatment groups. The response to the
investigational product was evaluated by the proportion of
responders defined as patients with ≥40% decrease in the
PANSS-EC total score at 2 hours after the first IM
injection from baseline.
During the 24-hour treatment period, safety was assessed
by clinical examination and laboratory investigations, andrecording spontaneously reported adverse events. The
severity of extrapyramidal symptoms was evaluated at
baseline and 24 hours after the initial administration
based on the Drug-Induced Extra-pyramidal Symptoms
Scale (DIEPSS) [24]. The ECGs were performed during
screening and at 2 and 24 hours after the first IM in-
jection. The ACES was used to evaluate the safety of
the investigational product in addition to its efficacy
evaluation, a score of 8 (Deep Sleep) or 9 (Unarousable)
was defined as oversedation.
Statistical evaluation
A total of 90 patients (45 patients per group) was deter-
mined to be the necessary sample size to verify that the
decrease in PANSS-EC was significantly greater in the
IM olanzapine group than in the IM placebo group, by a
Student’s t-test with a power of 90% at a 2-sided signifi-
cance level of 5%. Considering the variation of the effect
size in previous studies [25,26], total sample size was
conservatively set at 90 patients (45 patients per group).
Efficacy and safety analyses were conducted on the full
analysis set (FAS). This set principally included all data
from all randomized patients receiving at least 1 dose of
the study drug. The IM olanzapine group was compared
with the IM placebo group using an analysis of variance
(ANOVA) model which included treatment and site as
factors. For proportions, a Fisher’s exact test was used. All
statistical tests were performed at a 2-sided significance
level of 5%. The approach to handling missing data was
based on the last observation carried forward (LOCF).
The primary efficacy outcome was the LOCF change
in PANSS-EC total score from baseline to 2 hours after
the first IM injection. The LOCF change was compared
between the IM olanzapine and IM placebo groups,
using an ANOVA model which includes treatment and
the site as factors. The LOCF change in the PANSS-EC
total score from baseline to each evaluation timepoint
within 2 hours after the first injection and to 24 hours
after the first injection was compared between the 2
treatment groups.
A treatment-emergent adverse event (TEAE) was
defined as an untoward medical occurrence that newly
occurred or deteriorated after the first IM injection of
the investigational product. Each occurrence was coded
with reference to the Medical Dictionary for Regulatory
Activities (MedDRA) (version 13.1). The proportion of
patients with TEAEs, adverse drug reactions (ADRs)
(defined as adverse events possibly related to the investi-
gational product), serious adverse events (SAEs), TEAEs
leading to discontinuation, and severe TEAEs were com-
pared between the treatment groups. After the first IM
injection, the proportion of patients with an ACES score
of 8 (Deep Sleep) or 9 (Unarousable) were measured to
assess oversedation. The proportions of patients with
Table 1 Patient demographics
Item IM Olz,
10 mg
IM Placebo Total p
valuea
(N=45) (N=45) (N=90)
Age, years N 45 45 90 .812
Mean 46.4 47.0 46.7
SD 11.7 12.1 11.9
Min 20 23 20
Median 50.0 45.0 47.0
Max 63 65 65
Gender, n (%) Male 21 (46.7) 23 (51.1) 44 (48.9) .833
Female 24 (53.3) 22 (48.9) 46 (51.1)
BMI, kg/m2 N 45 45 90 .360
Mean 23.9 23.0 23.4
SD 4.9 4.1 4.5
Min 16.1 14.3 14.3
Median 23.4 22.5 23.0
Max 38.4 35.1 38.4
Age at onset, years N 44 45 89 .215
Mean 24.7 27.2 25.9
SD 9.4 9.3 9.4
Min 15 16 15
Median 22.0 25.0 23.0
Max 49 57 57
Abbreviations: BMI=body mass index; IM Olz=intramuscular olanzapine;
Max=maximum; Min=minimum; N= number of patients in analysis set;
n= number of patients in subset; SD=standard deviation.
ap value: Student's t test for continuous data, Fisher's exact test for
categorical data.
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blood pressure, pulse rate, and ECGs were compared
between the treatment groups. Treatment-emergent extra-
pyramidal symptoms were evaluated based on the DIEPSS
score. Parkinsonism (Gait, Bradykinesia, Sialorrhea, Muscle
Rigidity, and Tremor) was defined if a patient met 1 of the
following 3 criteria (score ≥3 on 1 item, score ≥2 on 2
items, or increase of ≥3 from baseline). If a patient met 1
of the first 2 criteria at baseline, the patient was excluded
from the analysis. Akathisia, Dystonia, and Dyskinesia were
defined if a patient met 1 of 2 criteria (score ≥2 or increase
of ≥2 from baseline). If a patient met the first criteria at
baseline, the patient was excluded from the analysis.
Ethics
The protocol of this study was prepared in accordance
with the ethical principles from the Declaration of Helsinki
and in compliance with the “Good Clinical Practice stan-
dards of pharmaceutical products” (GCP) and related laws
and regulations. This study was conducted in compliance
with the study protocol and GCP and related laws and
regulations. Prior to the study conduct, the study protocol,
case report forms, written explanation to patients and
informed consent form as well as the conduct of the study
were reviewed and approved by the institutional review
boards of the respective study sites. The name of the inves-
tigational review boards can be found in the Ethics ap-
proval section at the end of this manuscript. Prior to
initiation of the procedure and study drug administration,
the investigators or subinvestigators obtained consent to
participate in the study from the patients or their legal
representatives by their free wills. When the study was
conducted by the consent of a legal representative, the in-
vestigator or subinvestigator tried to obtain an additional
consent from the patient once he/she became able to give
consent. If the patient refused to give additional consent or
he/she requested withdrawal from the study, he/she was
able to be immediately withdrawn from the study.
Results
Of the 91 randomized patients in this study, 90 patients
(45 IM olanzapine-group patients; 45 IM placebo-group
patients) were in the FAS. One patient in the rando-
mized group was excluded from the FAS analysis due to
discontinuation by physician’s decision before the first
IM injection. Eighty-nine patients (45 IM olanzapine-
group patients; 44 IM placebo-group patients) were used
for the primary efficacy analysis. One patient in the FAS
group was excluded from the efficacy analysis because of
a problem in the maintenance of the blind. To be statis-
tically conservative, the FAS used for the safety analysis
included all patients who received study drug.
Table 1 summarizes the demographic characteristics for
the FAS by treatment group and in total. The mean agewas 46.7 years (range, 20–65 years); mean body mass
index, 23.4 kg/m2 (range, 14.3–38.4 kg/m2); and mean age
at onset, 25.9 years (range, 15–57 years). The proportion
of male patients was 46.7% in the IM olanzapine group
and 51.1% in the IM placebo group. Six of 90 patients
(6.7%) had diabetes mellitus at baseline (IM olanzapine,
historical n=1, pre-existing n=2; IM placebo, historical
n=0, pre-existing n=3). No statistically significant diffe-
rences were seen between the IM olanzapine and IM pla-
cebo groups at baseline in any demographic category. The
baseline PANSS-EC total score (mean ± standard devi-
ation [SD]) was 23.5±6.1 in the IM olanzapine group
and 23.3±4.9 in the IM placebo group (p=.638) (Table 2).
The baseline ACES score (mean ± SD) was 1.6±0.5 in the
IM olanzapine group and 1.6±0.5 in the IM placebo
group (p=.741). The baseline values showed no sig-
nificant difference between the 2 treatment groups.
The primary efficacy endpoint, the mean change of
PANSS-EC total score from baseline to 2 hours after the
first IM injection was −9.2±4.5 for the IM olanzapine
group and -2.8±5.6 for the IM placebo group (Table 2).
The difference between treatment groups was statistically
significant (p<.001) for the mean change of PANSS-EC
Table 2 Primary and secondary analyses, change from baseline to 2-hour timepoint (LOCF)
IM Olz, 10 mg (N=45) IM Placebo (N=44) p valueb
Mean (points) SD 95%CI Mean (points) SD 95%CI
Baseline
PANSS-EC total 23.5 6.1 21.7, 25.4 23.3 4.9 21.8, 24.8 .638
Poor impulse control 4.8 1.2 4.5, 5.2 4.7 1.2 4.3, 5.0 .336
Tension 4.7 1.6 4.2, 5.2 4.7 1.1 4.3, 5.0 .722
Hostility 4.6 1.6 4.1, 5.1 4.6 1.3 4.2, 5.0 .912
Uncooperativeness 4.7 1.3 4.3, 5.1 4.8 1.2 4.4, 5.1 .791
Excitement 4.7 1.2 4.4, 5.1 4.6 1.0 4.3, 4.9 .385
ACESa 1.6 0.5 1.5, 1.7 1.6 0.5 1.5,1.8 .741
2 hours
PANSS-EC total 14.3 6.0 12.5, 16.1 20.5 7.5 18.3, 22.8
Poor impulse control 3.0 1.3 2.6, 3.4 4.1 1.5 3.7, 4.6
Tension 2.9 1.2 2.5, 3.2 4.1 1.7 3.6, 4.6
Hostility 2.8 1.3 2.4, 3.1 4.0 1.7 3.5, 4.5
Uncooperativeness 2.9 1.4 2.5, 3.3 4.3 1.6 3.8, 4.8
Excitement 2.8 1.2 2.4, 3.2 4.0 1.5 3.5, 4.4
ACES 3.5 1.7 2.9, 4.0 2.2 1.3 1.8, 2.6
Change, baseline-2 hours
PANSS-EC Total −9.2 4.5 −10.6, -7.9 −2.8 5.6 −4.5, -1.1 <.001
Poor impulse control −1.9 1.0 −2.2, -1.6 −0.6 1.2 −0.9, -0.2 <.001
Tension −1.8 1.1 −2.2, -1.5 −0.6 1.1 −0.9, -0.2 <.001
Hostility −1.8 1.2 −2.2, -1.5 −0.6 1.5 −1.0, -0.1 <.001
Uncooperativeness −1.7 0.9 −2.0, -1.5 −0.5 1.2 −0.8, -0.1 <.001
Excitement −1.9 1.1 −2.3, -1.6 −0.6 1.4 −1.0, -0.2 <.001
ACES 1.9 1.5 1.4, 2.3 0.6 1.1 0.2, 0.9 <.001
Abbreviations: ACES=Agitation-Calmness Evaluation Scale; CI=confidence interval; IM Olz=intramuscular olanzapine; LOCF=last observation carried forward
[analysis]; N=number of patients with a baseline and a value at the time (LOCF); PANSS-EC=Positive and Negative Syndrome Scale-Excited Component.
aAt baseline placebo n=45.
bp value: ANOVA model which includes Treatment and Site as factors.
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timepoint, the IM olanzapine group showed a signifi-
cant decrease in all PANSS-EC individual item scores
compared with the IM placebo group.
The change from baseline to each evaluation timepoint
(15, 30, 60 and 90 minutes, and 2 and 24 hours after the
first IM injection) in PANSS-EC total scores was a
secondary efficacy endpoint. At every timepoint, statisti-
cally significant differences were observed between IM
olanzapine and IM placebo groups (p<.001) (Figure 1).
The maximum change in PANSS-EC total score in the
IM olanzapine group was observed at the 2-hour time-
point. At the 24-hour timepoint the mean change in
PANSS-EC total score in the IM olanzapine group
decreased to −5.6 (from −9.2 at 2 hours), while IM placebo
group remained at -2.8 (from −2.8 at 2 hours) (p=.008).
At 2 hours after the first IM injection, the proportion of
responders (≥40% decrease in the PANSS-EC total score)
was 40% (18/45 patients) in the IM olanzapine group and
13.6% (6/44 patients) in the IM placebo group. Thedifference between treatment groups in the proportion of
responders was statistically significant (p=.008).
At 2 hours after the first IM injection the mean
ACES score for IM olanzapine group was 3.5±1.7
(n=45) and in the IM placebo group the mean was
2.2±1.3 (n=44) (Table 2). The proportion of patients
with the ACES score of 4 (Normal) to 7 (Marked
Calmness) was evaluated at 2 hours after the first IM
injection. ACES scores fell between 4 and 7 in 40%
(18/45) of the IM olanzapine group and 13.6% (6/44)
of the IM placebo group (p=.008). The mean change
from baseline to 2 hours in ACES score for IM olan-
zapine (1.9±1.5) and IM placebo (0.6±1.1) groups was
statistically significantly different between groups
(p<.001).
Twenty patients (44.4%) in the IM olanzapine group
received a second IM olanzapine injection (10 mg) after
the first IM injection. Twenty-six patients (57.8%) in the
IM placebo group received the second IM injection after
the first IM injection (p=.292).
Figure 1 Time-course change from baseline in PANSS-EC total
score up to 24 hours after administration. PANSS-EC total score
for timepoint-wise change from baseline to 24 hours after the first IM
injection, full analysis set, IM Olz, 10 mg (n=45), IM Placebo (n=44).
Abbreviations: CI=confidence interval; IM Olz=intramuscular olanzapine
*statistically significant difference between groups.
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placebo-group patients) were analyzed for the safety
measures. Table 3 contains an overview of adverse events
reported during the study. Treatment-emergent adverse
events were reported in 19 of the 90 patients during the
study. Thirteen patients (28.9%) were in the IM olanza-
pine group, and 6 patients (13.3%) were in the IM pla-
cebo group. Only 2 TEAEs were reported in more than 1
patient, somnolence (IM olanzapine, n=7 [15.6%]; IM
placebo, n=2 [4.4%]; p=.157) and blood urine present
(IM olanzapine, n=0; IM placebo, n=2 [4.4%]; p=.494).
There were no significant differences in proportion of
patients with TEAEs between treatment groups. Severity
of all TEAEs was mild, except orthostatic hypotension
(IM olanzapine, n=1) and blood creatine phosphokinase
increased (IM placebo, n=1), which were moderate.Table 3 Adverse events




Item n (%) n (%) p valuea
TEAE 13 (28.9) 6 (13.3) .120
ADR 9 (20.0) 4 (8.9) .230
TEAE leading to discontinuation 0 (0.0) 0 (0.0) ———
Severe TEAE 0 (0.0) 0 (0.0) ———
Serious adverse event 0 (0.0) 0 (0.0) ———
Abbreviations: ADR= adverse drug reaction; IM Olz=intramuscular olanzapine;
N= number of patients in the full analysis set; n=number of patients with ≥1
event;TEAE=treatment-emergent adverse event.
ap value: Fisher's exact test.There were no statistically significant differences
between the IM olanzapine and IM placebo groups in
the proportion of patients with TEAEs (p=.120) or ADRs
(p=.230). There were no deaths, SAEs, TEAEs leading to
discontinuation, severe TEAEs, or instances of oversedation
in this study.
Treatment-emergent extrapyramidal symptoms such as
Parkinsonism, Akathisia, Dystonia, and Dyskinesia were
evaluated based on DIEPSS. Parkinsonism was observed
in the IM olanzapine group (2/43 patients, 4.7%), and in
the IM placebo group (3/44 patients, 6.8%) (p=1.000).
There were no incidences of treatment-emergent extra-
pyramidal symptoms of Akathisia, Dystonia, or Dyskinesia
at 24 hours after the first IM injections. There were no
significant differences between the IM olanzapine and
IM placebo groups in the proportion of patients using
benzodiazepines or anticholinergics.
There were no statistically significant differences between
treatment groups in the proportion of patients with poten-
tially clinically significant changes in laboratory tests, vital
signs (blood pressure and pulse rate), and ECGs. Two IM
olanzapine group patients had a QT interval corrected for
heart rate using Fridericia’s formula (QTcF) increase >30
msec at 2 hours and 1 IM olanzapine patient had an in-
crease >30 msec at 24 hours after the IM injection. No
patients in the IM placebo group showed a QTcF increase
>30 msec at 2 or 24 hours after the IM injection. No pa-
tient, at any timepoint, showed an increase greater than 60
msec, or a QTcF greater than 480 msec. The mean change
from baseline of QTcF was 1.6 msec for 2 hours, -2.6 msec
for 24 hours for the IM olanzapine group. The mean
change from baseline of QTcF was 4.1 msec for 2 hours,
and −1.1 msec for 24 hours for the IM placebo group.
These changes were not clinically significant and there were
no statistically significant differences between the groups.
Discussion
This was a placebo-controlled, double-blind confirmatory
study of rapid-acting IM olanzapine in acutely agitated
patients with schizophrenia. The primary objective of the
study was to confirm the efficacy of IM olanzapine (10 mg)
was greater than IM placebo in Japanese patients who had
exacerbation of schizophrenia with acute psychotic agita-
tion by comparing changes from baseline to 2 hours after
the first IM injection, as measured by PANSS-EC
total score. The study results showed a statistically
significant difference between the IM olanzapine and
IM placebo groups in the change from baseline to 2 hours
in PANSS-EC total score (p<.001).
Onset of action was fast, the baseline to each
evaluation timepoint in PANSS-EC total scores was sig-
nificantly different between the IM olanzapine and IM
placebo groups starting at 15 minutes. The efficacy of IM
olanzapine has been demonstrated previously in overseas
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Japanese patients.
This analysis did not show a statistically significant
difference in the incidence of TEAE between the IM
olanzapine group and the IM placebo group, and none
of the events occurred at a significantly higher incidence
in the IM olanzapine group compared with the IM pla-
cebo group. Somnolence was reported more often in IM
olanzapine group patients but this difference between
groups was not statistically significant. This may have
been due to the sample sizes. Clinically relevant change
was not observed with clinical laboratory data, vital
signs, and ECG in patients treated with IM olanzapine.
There were no patients who experienced oversedation as
measured by ACES. Treatment-emergent extrapyramidal
symptoms did occur during this study; however, the
proportion in the placebo group was higher (4.7% olan-
zapine versus 6.8% placebo, p=1.000). Metabolic adverse
events associated with glucose metabolism are often
discussed as potential risks of olanzapine treatment [27].
Although there were no clear signals of adverse events
or laboratory changes associated with glucose metabo-
lism in this study, it is important to monitor patients for
adverse events and laboratory changes associated with
glucose metabolism in clinical practice.
There were several limitations to this study. The current
study’s sample size was the necessary size to verify that the
decrease in PANSS-EC was significant; however a larger
sample size would have provided a better representation of
the real-world patient population. The patients enrolled in
this study were inpatients or outpatients who required
hospitalization, and there were very few treatment naïve
patients. Patients were required to show a minimum level
of cooperativeness with study procedures, so the sample
may not represent very severely agitated or combative
patients with schizophrenia.
The previous confirmative study in Japan did not have
a successful efficacy result [25]. One of the potential rea-
sons for the lack of a statistical difference in the primary
endpoint of the previous study was the inclusion of
patients unlikely to show a drug-placebo separation, like
patients with chronic agitation who are resistant to treat-
ment or patients with nonpsychotic agitation who may
respond to environmental interventions. In the current
study as opposed to the previous study, additional inclu-
sion and exclusion criteria were added. The exacerbation
of schizophrenia with acute psychotic agitation was
added as an inclusion criterion, and continuous agitation
in patients for at least 2 weeks duration before informed
consent was to be signed was added as an exclusion cri-
terion. This was done to exclude patients who were re-
sistant to treatment and showed high PANSS-EC total
score chronically. In addition, to exclude patients with non-
psychotic agitation who could respond to environmentalinterventions, we set some specific exclusion criteria, such
as the comorbidity of mental retardation or personality
disorders that are more likely to show nonpsychotic reac-
tive excitement and placebo response. These changes in
inclusion and exclusion criteria have likely contributed to
the current successful results.
Conclusion
It was confirmed that the efficacy of IM olanzapine 10 mg
was greater than IM placebo in patients who had exacer-
bation of schizophrenia with acute psychotic agitation as
evaluated by the primary efficacy measure, PANSS-EC.
There were no deaths, SAEs, TEAEs leading to discon-
tinuation, severe TEAEs, or instances of oversedation in
this study. Intramuscular olanzapine 10 mg was shown to
be generally safe and tolerable in acutely agitated patients
with schizophrenia.
Olanzapine rapid IM injection preparation demon-
strated efficacy and safety in patients who had exacerba-
tion of schizophrenia with acute psychotic agitation, and
it could be a new option for treatment of schizophrenia
with severe agitation, which cannot be treated with oral
medication, in Japan.
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